NCT02362139|UnknownPhase 3DMC
Loading search results
Sponsor study identifier
interventional
400
0 countries
N/A
Study Start
February 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
In the investigators institution, there is a wide use of Papaverine in delivery room, but this use is optional, and is left to the discretion of the physician. The aim of the investigators study is to prospectively evaluate the influence of Papaverine administration in the latent phase of labor, on the duration of labor.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2015
Date type not reportedThis date has not been verified as actual or estimated.
February 8, 2015
Actual (reported)February 12, 2015
Actual (reported)February 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
February 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The duration of time between Papaverine administration and delivery.
24 month
Duration of second and third stages of labor
24 month
Cervical dilatation rate (cm\Hr)
24 month
Papaverine adverse outcome
24 month
200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Eran Ashwal, MD
Rabin Medical Center
First Submitted
February 8, 2015
First Posted
February 12, 2015
Study Start
February 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2017
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 12, 2015
Record last verified: 2015-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: